Adicet announces appointment of dr. michael g. kauffman to the board of directors

Menlo park, calif. and boston, nov. 18, 2021 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing first-in-class allogeneic gamma delta t cell therapies for cancer and other diseases, today announced the appointment of michael g. kauffman, m.d., ph.d., to its board of directors.

ACET Ratings Summary

ACET Quant Ranking